Success Metrics

Clinical Success Rate

57.1%

Based on 4 completed trials

Completion Rate

57%(4/7)

Active Trials

0(0%)

Results Posted

25%(1 trials)

Terminated

3(38%)

Phase Distribution

Ph phase_3

13%

Ph not_applicable

38%

Ph phase_4

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 3Large-scale testing

1(14.3%)

Phase 4Post-market surveillance

3(42.9%)

N/ANon-phased studies

3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(3)

Other(1)

Detailed Status

Completed4

Terminated3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

57.1%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (14.3%)

Phase 43 (42.9%)

N/A3 (42.9%)

Trials by Status

completed450%

terminated338%

unknown113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_4

Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response

NCT02437045

terminatedphase_4

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

NCT01694069

terminatednot_applicable

LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

NCT02840136

completed

AbioKin - Antibiotic Kinetics

NCT02609646

completedphase_3

Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis

NCT02619149

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02437045Phase 4

Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response

Completed

NCT01694069Phase 4

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Terminated

NCT02840136Not Applicable

LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

Terminated

NCT02609646

AbioKin - Antibiotic Kinetics

Completed

NCT02619149Phase 3

Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis

Completed

NCT02176122Phase 4

RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.

Terminated

NCT01714570Not Applicable

Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

Completed

NCT01714557Not Applicable

Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation

Unknown

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8